The changing landscape of hepatitis C virus therapy: Focus on interferon-free treatment

Therapeutic Advances in Gastroenterology

Volumn 8, Issue 5, 2015, Pages 298-312

  Lam, Brian P ^a   Jeffers, Thomas ^a   Younoszai, Zahra ^a   Fazel, Yousef ^a   Younossi, Zobair M ^b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b Betty and Guy Beatty Center for Integrated Research   (United States)

Author keywords

direct acting antiviral agents; Harvoni; ledipasvir; paritaprevir; sofosbuvir; Viekira

Indexed keywords

ABT 530; ALPHA INTERFERON; ANTIVIRUS AGENT; ASUNAPREVIR; BECLABUVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ELBASVIR; GRAZOPREVIR; INTERFERON; JNJ 845; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; MK 3682; NONSTRUCTURAL PROTEIN 5A INHIBITOR; RADALBUVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; TMC 055; UNCLASSIFIED DRUG; VEDROPREVIR; VELPATASVIR;

ANEMIA; ANXIETY DISORDER; CAUSE OF DEATH; CHRONIC HEPATITIS C; COHORT ANALYSIS; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FLU LIKE SYNDROME; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; IMMUNOPATHOLOGY; INSOMNIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MORTALITY; NAUSEA; NEUTROPENIA; NONHUMAN; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; PSYCHOPATHY; QUALITY OF LIFE; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRAL CLEARANCE;

EID: 84943230055     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X15587481     Document Type: Review

References (43)

1. AbbVie Inc. (2015 a) Viekira Pak (prescribing information). North Chicago, Illinois: AbbVie Inc.
2. AbbVie Ltd (2015 b) Exviera (prescribing information). Maidenhead, UK: AbbVie Ltd.
3. AbbVie Ltd (2015 c) Viekirax (prescribing information). Maidenhead, UK: AbbVie Ltd.
4. Afdhal N. Reddy K. Nelson D. Lawitz E. Gordon S. Schiff E. et al. ION-2 Investigators (2014 a) Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370: 1483–1493.
5. Afdhal N. Zeuzem S. Kwo P. Chojkier M. Gitlin N. Puoti M. et al. ION-1 Investigators (2014 b) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370: 1889–1898.
6. Andreone P. Colombo M. Enejosa J. Koksal I. Ferenci P. Maieron A. et al. (2014) ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 147: 359–365.
7. Armstrong G. Wasley A. Simard E. McQuillan G. Kuhnert W. Alter M. (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144: 705–714.
8. Chak E. Talal A. Sherman K. Schiff R. Saab S. (2011) Hepatitis C virus infection in USA. Liver Int 31: 1090–1101.
9. Chen S. Morgan T. (2006) The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 3: 47–52.
10. D'Ambrosio R. Aghemo A. Rumi M. Ronchi G. Donato M. Paradis V. et al. (2012) A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 56: 532–543.
11. Davis G. Alter M. El-Serag H. Poynard T. Jennings L. (2010) Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138: 513–521.
12. Dieterich D. Bacon B. Flamm S. Kowdley K. Milligan S. Tsai N. et al. (2014) Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology 60: S-220A.
13. Feld J. Kowdley K. Coakley E. Sigal S. Nelson D. Crawford D. et al. (2014) Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370: 1594–1603.
14. Feld J. Hoofnagle J. (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967–972.
15. Ferenci P. Bernstein D. Lalezari J. Cohen D. Luo Y. Cooper C. et al. (2014) ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 370: 1983–1992.
16. Hézode C. Fontaine H. Dorival C. Zoulim F. Larrey D. Canva V. et al. CUPIC Study Group (2014) Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 147: 132–142.
17. Jensen D. O'Leary J. Pockros P. Sherman K. Kwo P. Mailliard M. et al. (2014) Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort. Hepatology 60: S-220A.
18. Kohli A. Sims Z. Nelson A. Osinusi A. Tefari G. Pang P. et al. (2014) Combination oral, hepatitis C antiviral therapy for 6 or 12 weeks: final results of the SYNERGY trial (CROI abstract 27LB). special issue: Abstracts From the 2014 Conference on Retroviruses and Opportunistic Infections. Top Antivir Med 22: 14–15.
19. Kowdley K. Gordon S. Reddy K. Rossaro L. Bernstein D. Lawitz E. et al. ION-3 Investigators (2014) Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370: 1879–1888.
20. Lam B. Henry L. Younossi Z. (2014) Sofosbuvir (Sovaldi) for the treatment of hepatitis C. Expert Rev Clin Pharmacol 7: 555–566.
21. Lawitz E. Sulkowski M. Ghalib R. Rodriguez-Torres M. Younossi Z. Corregidor A. et al. (2014) Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384: 1756–1765.
22. McHutchison J. Manns M. Patel K. Poynard T. Lindsay K. Trepo C. et al. International Hepatitis Interventional Therapy Group (2002) Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123: 1061–1069.
23. McHutchison J. Ware J. Jr Bayliss M. Pianko S. Albrecht J. Cort S. et al. (2001) The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 34: 140–147.
24. McHutchison J. Sulkowski M. (2008) Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat 15: 475–481.
25. Messina J. Humphreys I. Flaxman A. Brown A. Cooke G. Pybus O. et al. (2014) Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. Epub ahead of print 28 July 2014. DOI: 10.1002/hep.27259.
26. Mohd Hanafiah K. Groeger J. Flaxman A. Wiersma S. (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57: 1333–1342.
27. Ng V. Saab S. (2011) Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 9: 923–930.
28. Poordad F. Hezode C. Trinh R. Kowdley K. Zeuzem S. Agarwal K. et al. (2014) ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370: 1973–1982.
29. Rein D. Wittenborn J. Weinbaum C. Sabin M. Smith B. Lesesne S. (2011) Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 43: 66–72.
30. Rutter K. Hofer H. Beinhardt S. Dulic M. Gschwantler M. Maieron A. et al. (2013) Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral. Aliment Pharmacol Ther 38: 118–123.
31. Shiffman M. Sterling R. Contos M. Hubbard S. Long A. Luketic V. et al. (2014) Long term changes in liver histology following treatment of chronic hepatitis C virus. Ann Hepatol 13: 340–349.
32. Smith B. Morgan R. Beckett G. Falck-Ytter Y. Holtzman D. Ward J. (2012) Hepatitis C virus testing of persons born during 1945–1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 157: 817–822.
33. Suryaprasad A. White J. Xu F. et al. (2014) Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Infect Dis 59: 1411–1419.
34. Tempestilli M. Lionetti R. D'Offizi G. Montalbano M. Giaffreda A. Fazio S. et al. (2014) Increased plasma concentration of ribavirin as a result of renal dysfunction in hepatitis C virus patients treated with telaprevir. Hepatology 60: 1109–1110.
35. Younossi Z. Jiang Y. Smith N. Smith N. Stepanova M. Beckerman R. (2015 a) Ledipasvir / sofosbuvir regimens for chronic hepatitis C infection: insights from a work productivity economic model from the United States. Hepatology 64: 1471–1478.
36. Younossi Z. Kanwal F. Saab S. Brown K. El-Serag H. Kim W. et al. (2014 a) The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 39: 518–531.
37. Younossi Z. Stepanova M. Afdhal N. Kowdley K. Zeuzem S. Henry L. et al. (2015 b) Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. Epub ahead of print 17 March 2015. DOI: 10.1016/j.jhep.2015.03.014.
38. Younossi Z. Stepanova M. Henry L. Gane E. Jacobson I. Lawitz E. et al. (2014 b) Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 12: 1349–1359.
39. Younossi Z. Stepanova M. Marcellin P. Afdhal N. Kowdley K. Zeuzem S. et al. (2015 c) Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatology. Epub ahead of print 27 January 2015. DOI: 10.1002/hep.27724.
40. Younossi Z. Stepanova M. Nader F. Jacobson I. Gane E. Nelson D. et al. (2014 c) Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology 59: 2161–2169.
41. Younossi Z. Stepanova M. Sulkowski M. Naggie S. Puoti M. Orkin C. et al. (2015 d) Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes. J Infect Dis. Epub ahead of print 12 January 2015 PII: jiv005.
42. Younossi Z. Stepanova M. Zeuzem S. Dusheiko G. Esteban R. Hezode C. et al. (2014 d) Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study. J Hepatol 61: 228–234.
43. Zeuzem S. Jacobson I. Baykal T. Marinho R. Poordad F. Bourlière M. et al. (2014) Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370: 1604–1614.